SHR-A1811 Shows Promising Activity in HR+/HER2-Low Breast Cancer
SHR-A1811, a novel anti-HER2 antibody drug conjugate (ADC), demonstrated promising anti-tumor activity and an acceptable safety profile in the neoadjuvant setting in patients with hormone receptor (HR)–positive/HER2-low breast cancer, according to …